

Special Issue

Drug-Resistant Bacterial Infections and Alternative Therapies

Message from the Guest Editor

Dear Colleagues Antibiotic resistance has emerged as a global healthcare challenge and therapeutic options for treating antibiotic-resistant infections are shrinking. Antibiotic resistance limits the effectiveness of existing antibiotics and complicates the treatment of infectious diseases. Addressing antibiotic resistance requires a multifaceted approach, and the development of novel alternatives to antibiotics is crucial to combat resistance, which includes the discovery/development of novel antibacterial agents, phages, enzybiotics, plant extracts, antibacterial nanoparticles, etc. These antibacterial agents may offer potential benefits in treating infections when used alone or in combination with available therapeutic options. This Special Issue is focused on publishing primary research and review articles that explore novel therapeutic agents which could be used as an alternative to conventional antibiotics in managing drug-resistant bacterial infections.

Guest Editor

Dr. Vijay Singh Gondil

Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14620, USA

Deadline for manuscript submissions

closed (30 September 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/173229

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).